Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

This study tests whether adding a device called Tumor Treating Fields (a wearable device that uses electrical fields to slow cancer growth) to standard chemotherapy improves outcomes in patients with locally advanced pancreatic cancer that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic cancer (adenocarcinoma) confirmed by biopsy - Your cancer is locally advanced (grown into nearby blood vessels) but has not spread to distant organs - Your overall health is good enough to receive chemotherapy (ECOG score 0–1) - Your expected survival is at least 3 months - You have not yet received any treatment for your pancreatic cancer **You may NOT be eligible if...** - You have already received chemotherapy for pancreatic cancer - You are allergic to gemcitabine or albumin-bound paclitaxel (the chemotherapy drugs used) - You have another active cancer (except certain treated early-stage cancers) - Your blood counts, liver, kidney, or heart function are significantly abnormal - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.